Parkinson's drug study aims to uncover disease clues
NCT ID NCT05677633
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the safety of a drug called sargramostim (Leukine) in 11 people with Parkinson's disease over 48 weeks. Researchers also looked for changes in immune cells and other biomarkers that might help track the disease. The goal was not to cure Parkinson's but to better understand how the body responds to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sargramostim (Leukine)
What this could lead to
If successful, this study could help identify biomarkers that track Parkinson's disease progression and response to treatment, potentially guiding future therapies.
What could go wrong
This is a very small, early-phase trial with only 11 participants, focused on safety and biomarker validation rather than proving effectiveness. Results may not apply to all Parkinson's patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE AND PARKINSONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States